About Desmopressin
Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin
Desmopressin (DDAVP) is a synthetic analogue of arginine vasopressin (AVP) and an FDA-approved prescription medication indicated for central diabetes insipidus, primary nocturnal enuresis, and bleeding management in mild hemophilia A and von Willebrand disease type I. It exerts its primary therapeutic effects through V2 receptor activation in the renal collecting duct, increasing water reabsorption, and through DDAVP-mediated release of von Willebrand factor and factor VIII from endothelial storage sites. Research has also explored desmopressin effects on memory consolidation through vasopressinergic pathways in the brain, though controlled trials in healthy volunteers have produced inconsistent results, with some studies finding no measurable cognitive benefit. Desmopressin is available as nasal spray, sublingual tablet, and injectable formulations; use outside approved indications requires physician supervision, and hyponatremia is a documented and potentially serious risk, particularly in elderly patients. Desmopressin dosage and clinical contexts Desmopressin is available in three formulations with distinct dosing parameters. The nasal spray (DDAVP nasal spray, 100mcg/mL) is dosed at 10–40mcg once or twice daily for central diabetes insipidus; the intranasal formulation is no longer approved for primary nocturnal enuresis in adults due to hyponatremia risk. Oral/sublingual tablets (DDAVP, Nocdurna, Noctiva) are used for nocturia (a newly prominent indication: Nocdurna 25/50mcg sublingual) and primary nocturnal enuresis (0.1–0.4mg). Injectable desmopressin (4mcg/mL) is used perioperatively for hemophilia A and von Willebrand disease bleeding management at 0.3mcg/kg IV. The sublingual formulation for nocturia in adults (Nocdurna, FDA-approved 2018) represents a significant expanded indication — nocturia affects a large proportion of older adults, and desmopressin's water-retention mechanism can reduce nightly urination frequency. Desmopressin vs vasopressin: Desmopressin is a structural modification of vasopressin — deamination of the N-terminal cysteine and substitution of D-arginine for L-arginine — that eliminates vasopressor (V1a receptor) activity while preserving antidiuretic (V2 receptor) potency, and dramatically extends the half-life from ~10 minutes to 1.5–3 hours. This selectivity makes desmopressin clinically safer than vasopressin for antidiuretic indications; vasopressin is reserved for contexts requiring vasopressor activity (septic shock, vasodilatory shock).
Desmopressin Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
- Effective Date
- January 1, 1978
- Source
- View FDA source →
FDA-approved synthetic vasopressin analog. Brands: DDAVP (NDA 017922), Stimate, Nocdurna (NDA 201532, Jun 2018). Approved forms: injection, intranasal, oral, sublingual. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
7 sources cited · 5 moderate · 2 weak
1 RCT · 4 Cohorts · 2 Case seriess
Clinical Outcomes Following Supply-Driven Transition From Intranasal to Oral Desmopressin in AVP-Deficiency
Clinical Endocrinology · 2026
Research in 42 patients with arginine vasopressin deficiency transitioning from intranasal to oral desmopressin found that initial 1:10 conversion ratios led to symptomatic recurrence in over half of patients, with higher conversion ratios near 1:15 providing better initial control, highlighting the pharmacokinetic complexity of desmopressin formulations and the need for individualized dose titration.
Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2020-2023).
Int J Urol · 2026
# Summary Research found that desmopressin prescriptions in Japan increased nearly fourfold among men between 2020 and 2023, with over 90% of prescriptions issued to individuals aged 65 years and older. This study demonstrated that older patients were increasingly prescribed the lower-dose formulation, and off-label use in women was also rising, suggesting clinicians may be prioritizing safety in elderly populations while expanding treatment to unapproved populations.
Perioperative aspirin discontinuation prior to burr-hole drainage for chronic subdural hematoma: A European multicenter retrospective cohort study.
Clin Neurol Neurosurg · 2026
# Summary This study demonstrated that continuing aspirin perioperatively prior to burr-hole drainage for chronic subdural hematoma was associated with significantly higher rates of early postoperative hemorrhagic events (21.1%) compared to discontinuing aspirin either short-term or long-term (0-4.4%). Research found that aspirin discontinuation, regardless of timing, substantially reduced acute bleeding complications within 48 hours after surgery without increasing thromboembolic events.
Show 4 more sources ↓
Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.
J Pediatr Hematol Oncol · 2026
# Summary Research found that desmopressin was used less frequently than antifibrinolytics in the treatment management of inherited platelet function disorders, despite being available as a hemostatic option for patients across various IPFD subtypes. This study demonstrated that antifibrinolytics were the most commonly utilized treatment, used in over half of all IPFD patients in the national cohort.
Failure of posttrial administration of vasopressin analogue (DDAVP) to influence memory in healthy, young, male volunteers
Peptides · 1995
Research in a double-blind randomized controlled trial found that post-trial intranasal DDAVP 60 μg had no significant effect on 24-hour recall of learned prose passages in healthy young male volunteers, suggesting that vasopressin analogs influence memory acquisition rather than the consolidation of newly learned information.
Central Diabetes Insipidus Following Steroid Replacement for Hypoadrenalism in Pembrolizumab-Induced Hypophysitis.
Cureus · 2026
# Summary This study demonstrated that desmopressin treatment was effective in achieving clinical and biochemical recovery in a patient who developed central diabetes insipidus as part of pembrolizumab-induced hypophysitis. The research highlights how glucocorticoid replacement therapy can unmask underlying pituitary dysfunction that may not be initially apparent when multiple endocrine abnormalities occur simultaneously.
Adult-Onset Multisystem Langerhans Cell Histiocytosis: Atypical Skeletal and Endocrine Manifestations.
Cureus · 2026
# Summary This study demonstrated that a 55-year-old patient with adult-onset Langerhans cell histiocytosis presented with an atypical combination of multifocal bone lesions in the lower extremity and pituitary involvement (manifesting as central diabetes insipidus), which was successfully managed with systemic chemotherapy combined with endocrine replacement therapy including desmopressin. Researchers observed durable disease control over 70 months of follow-up, highlighting that LCH should be considered in adults presenting with unexplained multifocal lytic bone lesions accompanied by endocrine dysfunction.
Desmopressin Side Effects & Safety Considerations
Moderate risk profile. Review all reported considerations carefully before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Desmopressin — Providers & Availability
2 providersOnline Vendors
1 providerStay updated on verified Desmopressin providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Desmopressin
Desmopressin (DDAVP) is a synthetic analogue of arginine vasopressin (AVP) and an FDA-approved prescription medication indicated for central diabetes insipidus, primary nocturnal enuresis, and bleeding management in mild hemophilia A and von Willebrand disease type I. It exerts its primary therapeutic effects through V2 receptor activation in the renal collecting duct, increasing water reabsorption, and through DDAVP-mediated release of von Willebrand factor and factor VIII from endothelial storage sites.
memory consolidation, learning enhancement, antidiuretic, hemostasis.
Research on Desmopressin primarily documents effects related to memory consolidation and learning enhancement and antidiuretic and hemostasis. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Desmopressin include hyponatremia, heart failure, uncontrolled hypertension. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
2 providers in the directory currently offer Desmopressin.
Research in 42 patients with arginine vasopressin deficiency transitioning from intranasal to oral desmopressin found that initial 1:10 conversion ratios led to symptomatic recurrence in over half of patients, with higher conversion ratios near 1:15 providing better initial control, highlighting the pharmacokinetic complexity of desmopressin formulations and the need for individualized dose titration.